Luteinizing hormone-releasing hormone analogue-induced cataract in a patient with prostate cancer.
OBJECTIVE
To report a case of right posterior subcapsular cataract induced by 3-monthly depot luteinizing hormone-releasing hormone (LHRH) analogue therapy in a patient with early prostate cancer.


METHODS
A 52-year-old male with static myopia of several years' duration was given a 3-month depot LHRH analogue (goserelin 10.8 mg) as part of neoadjuvant treatment for early prostate cancer. Four weeks after the treatment, the patient developed right posterior subcapsular cataract commonly associated with steroid treatment. The patient had right eye cataract extraction followed by insertion of a new lens.


CONCLUSIONS
This report shows a case of a posterior subcapsular cataract as an adverse reaction to depot goserelin acetate. This is a feature commonly seen in steroid-induced cataract. Patients with prostate cancer and poor vision if due to cataract may not be ideal patients for depot preparations of LHRH analogues.
Al-Enezi
Ahmad
A
Department of Surgery, Division of Urology, Mubarak Al-Kabeer Teaching Hospital, Kuwait.
Kehinde
Elijah O
EO
Behbehani
Abdulla M
AM
Sheikh
Zafar A
ZA
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D002386:Cataract / Q000139:chemically induced*; D002387:Cataract Extraction; D017273:Goserelin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin